FIGURE 3 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

<p>Heat map of plasma proteins significantly changed (log₂ fold change) between cycle 2 day 1 and cycle 4 or 6 day 1 in treatment groups itacitinib + pembrolizumab (Part 1b Group A-1/A-2) or parsaclisib + pembrolizumab (Part 1b Group B-1/B-2, and Part 2). <b>A,</b> Interferon-inducible proteins reproducibly observed to increase following treatment with an anti-PD-1 antibody (e.g., pembrolizumab); IFN-inducible proteins were not induced in the itacitinib (JAK1 inhibitor) cotreatment arms (Group A-1/A-2). <b>B,</b> Proteins weakly increased in itacitinib-treated arm, no identifiable common pathway. <b>C,</b> Proteins decreased in the parsaclisib-treated (PI3Kδ inhibitor) arms, especially with high-dose parsaclisib (Group B-1/B-2), but less pronounced with low-dose (0.3 mg) parsaclisib (Part 2). <b>D,</b> Proteins decreased in the itacitinib-treated arms (Group A-1/A-2), involved in NK- and/or T-cell activation. <b>E,</b> Proteins decreased in high-dose parsaclisib-treated arms (Group B-1/B-2), highly enriched for proteins involved in T-cell, NK-cell, and macrophage function. C, cycle; D, day; JAK1, Janus kinase 1; NK, natural killer.</p>

Duke Scholars

Author Niharika Bansal Mettu Medicine, Medical Oncology